The human papillomavirus (HPV) is a crucial but not the predominant cause of cervical cancer. This study aimed to identify HPV-16 L1 gene expression in human papillomavirus using a pap smear. A total of 120 serum samples, 60 samples were taken from infected females with papillomavirus and another 60 as healthy control. These samples were collected after pap smears were done. These women attended Al-Emam Hospital for delivery from March 1st, 2021, to February 28th, 2022. The levels of Pap-IgM and Pap-IgG were increasing among patients attacked by papilloma. The levels of viruses were higher than in levels than control groups, which was indicated by increases in the scores of mean and standard deviation (2.01±1.17, 0.11±0.02), (14.24±7.10, 0.4±0.17), respectively. Statistically, these differences between the levels of the studied groups were highly significant. The levels of the three markers Ca19.9, Ca125, and Ca15.3 were normal in levels among papilloma patients and the control group compared to the normal value of the three markers, which equaled N.V. (>37ng/ml). Statistically, these differences between the scores of the three markers, which were measured depending on mean and standard deviation, were highly significant. There is a low positive correlation between the levels of Pap-IgM (>1) with levels of Ca19.9 (>37) with (r=0.409**, P=0.000), while there is a moderate association between the levels of Pap-IgM (>1) with Ca125 (>35ng/ml) and Ca15.3 (>37ng/ml) levels with (r=0.574**, 0.565**, P=0.000, 0.000) respectively. Also, this table documents that there is a moderate positive correlation between the levels of Pap-IgG (>1) and the levels of the three tumor markers Ca19.9 (>37), Ca125 (>35), and Ca15.3 (>37) (r=0.521**, 0.592**, 0.647**). The HPV-16 L1 gene expression was investigated in patients infected with Papillomaviruses compared to healthy controls using real-time PCR. The results showed a high Ct value for patients and controls with a high Ct value of templates, preoperational to the gene concentration. |
- Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1.
- Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public health. 2021;8:552028.
- Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27-41.
- Tempera I, Lieberman PM. Oncogenic Viruses as Entropic Drivers of Cancer Evolution. Front Virol. 2021;1.
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e90.
- Monteiro JC, Fonseca RRDS, Ferreira TCDS, Rodrigues LLS, Da Silva ARB, Gomes ST, et al. Prevalence of high risk HPV in HIV-Infected women from Belém, Pará, Amazon region of Brazil: a cross-sectional study. Front Public Health. 2021;9:649152.
- Patzi-Churqui M, Terrazas-Aranda K, Liljeqvist J-Å, Lindh M, Eriksson K. Prevalence of viral sexually transmitted infections and HPV high-risk genotypes in women in rural communities in the Department of La Paz, Bolivia. BMC Infect Dis. 2020;20(1):1-11.
- Magaña‐Contreras M, Contreras‐Paredes A, Chavez‐Blanco A, Lizano M, Cruz‐Hernandez YDl, Cruz‐Hernandez EDl. Prevalence of sexually transmitted pathogens associated with HPV infection in cervical samples in a Mexican population. J Med Virol. 2015;87(12):2098-105.
- Laantri N, Attaleb M, Kandil M, Naji F, Mouttaki T, Belghmi K, et al. Human papillomavirus detection in moroccan patients with nasopharyngeal carcinoma. Infect Agents Cancer. 2011;6(1):1-6.
- Ma X, Yang M. The correlation between high-risk HPV infection and precancerous lesions and cervical cancer. Am J Transl Res. 2021;13(9):10830.
- Kerishnan JP, Gopinath SC, Kai SB, Tang T-H, Ng HL-C, Rahman ZAA, et al. Detection of human papillomavirus 16-specific IgG and IgM antibodies in patient sera: a potential indicator of oral squamous cell carcinoma risk factor. Int J Med Sci. 2016;13(6):424.
- Katar M. Evaluation of tumor marker test requests in a hospital setting. Int J Med Biochem. 2021;4(1):8.
- Ayhan A, Guven S, Seda Guvendag Guven E, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand. 2007;86(4):484-90.
- Jayapalan S, Bindu R. Papanicolaou smear: A diagnostic aid in sexually transmitted infections. Indian J Sex Transm Dis Aids. 2020;41(2):143.
|